You have been logged out of VisualDx or your session has expired.

Please reload this page and sign into VisualDx to continue.

  VisualDx Mobile   Select Language

Get VisualDx Mobile

There are VisualDx mobile apps available for iOS and Android devices.

You will need a VisualDx account to use the mobile apps.

Already have an account? Sign In or
sign up for a free trial.

Users with VisualDx accounts earn CME credits for using VisualDx.

Already have an account? Sign In or
sign up for a free trial.

Create a Personal Account

E-mail (username)
Verify Password
First Name
Last Name

Personal Account Created

Mobile Access

You can now download VisualDx for your iOS and Android devices. Launch the VisualDx app from your device and sign in using your VisualDx personal account username and password.

CME Certification

Sign in with your personal account to earn and claim CME credits through VisualDx. Credits can be earned by building a differential or looking up a diagnosis.

Version: 7.10.1411   (build 9a43f6a)
Select Language

Select Region

Send us your feedback

This field is required

Oops! There was an issue during submission. Please try again. If the problem persists, email with your feedback.

Thank You!

We appreciate your feedback and you will be hearing from us soon.


Share This Page

Thank You!

We have sent an e-mail with a link to the current page.


E-mail This Patient Information Sheet

Thank You!

We have sent an e-mail with this patient information.


Image Contributors


  • Christine Ahn MD
    Carl Allen DDS, MSD
    Brandon Ayres MD
    Howard P. Baden MD
    Robert Baran MD
    Keira Barr MD
    Gregory J. Basura MD, Ph.D
    Donald Belsito MD
    Jeffrey D. Bernhard MD
    Jesse Berry MD
    Victor Blanco MD
    Benjamin R. Bohaty MD
    William Bonnez MD
    Sarah Brenner MD
    Robert A. Briggaman MD
    Robert Brodell MD
    Roman Bronfenbrener MD
    Walter Brooks MD
    William Buckley MD
    Philip Bulterys MD, PhD (candidate)
    Susan Burgin MD
    Sonya Burton MD
    Sean P. Bush MD, FACEP
    Jeffrey Callen MD
    Scott Camazine MD
    Michael Cardwell
    Shelley D. Cathcart MD
    Robert Chalmers MD, MRCP, FRCP
    Chia-Yu Chu MD, PhD
    Flavio Ciferri MD
    Maria Rosa Cordisco MD
    Noah Craft MD, PhD
    John T. Crissey MD
    Harold E. Cross MD, PhD
    Charles Crutchfield III MD
    Adriana Cruz MD
    Donna Culton MD, PhD
    Bart J. Currie MBBS, FRACP, DTM&H
    Chicky Dadlani MD
    Alexander Dane DO
    C. Ralph Daniel III MD
    Thomas Darling MD, PhD
    William Delaney MD
    Damian P. DiCostanzo MD
    Ncoza Dlova MD
    James Earls MD
    Libby Edwards MD
    Melissa K. Egge MD
    Charles N. Ellis MD
    Rachel Ellis MD
    David Elpern MD
    Nancy Esterly MD
    Stephen Estes MD
    E. Dale Everett MD
    Janet Fairley MD
    David Feingold MD
    Benjamin Fisher MD
    Henry Foong MBBS, FRCP
    David Foster MD, MPH
    Brian D. Foy PhD
    Michael Franzblau MD
    Vincent Fulginiti MD
    Sunir J. Garg MD, FACS
    Kevin J. Geary MD
    Lowell Goldsmith MD, MPH
    Sethuraman Gomathy MD
    Bernardo Gontijo MD, PhD
    Kenneth Greer MD
    Kenneth G. Gross MD
    Alan Gruber MD
    Nathan D. Gundacker MD
    Akshya Gupta MD
    Vidal Haddad MSC, PhD, MD
    Edward Halperin MD, MA
    Ronald Hansen MD
    John Harvey
    Rizwan Hassan MD
    Michael Hawke MD
    Jason E. Hawkes MD
    Peter W. Heald MD
    David G. Hicks MD
    Sarah Hocker DO
    Ryan J. Hoefen MD, PhD
    Li-Yang Hsu MD
    William Huang MD
    Sanjana Iyengar MD
    Alvin H. Jacobs MD
    Shahbaz A. Janjua MD
    Joshua J. Jarvis MD
    Kit Johnson
    Robert Kalb MD
    A. Paul Kelly MD
    Henry Kempe MD
    Loren Ketai MD
    Sidney Klaus MD
    Ashwin Kosambia MD
    Jessica A. Kozel MD
    Carl Krucke
    Mario E. Lacouture MD
    Joseph Lam MD
    Alfred T. Lane MD
    Edith Lederman MD
    Nahyoung Grace Lee MD
    Pedro Legua MD, PhD
    Robert Levin MD
    Bethany Lewis MD
    Sue Lewis-Jones FRCP, FRCPCH
    Taisheng Li MD
    Christine Liang MD
    Shari Lipner MD, PhD
    Jason Maguire MD
    Mark Malek MD, MPH
    Jere Mammino DO
    Ricardo Mandojana MD
    Lynne Margesson MD
    Thomas J. Marrie MD
    Maydel Martinez MD
    Ralph Massey MD
    Patrick McCleskey MD
    Karen McKoy MD
    Thomas McMeekin MD
    Josette McMichael MD
    Somchai Meesiri MD
    Joseph F. Merola MD
    Mary Gail Mercurio MD
    Anis Miladi MD
    Larry E. Millikan MD
    Dan Milner Jr. MD
    Zaw Min MD
    Stephanie Montero
    Alastair Moore MD
    Keith Morley MD
    Dean Morrell MD
    Samuel Moschella MD
    Taimor Nawaz MD
    Vic Newcomer MD
    John Nguyen MD
    Matilda Nicholas MD
    Thomas P. Nigra MD
    Steven Oberlender MD, PhD
    Maria Teresa Ochoa MD
    Art Papier MD
    Lawrence Parish MD
    Tanner Parrent MD
    Mukesh Patel MD
    Lauren Patty-Daskivich MD
    David Peng MD, MPH
    Robert Penne MD
    Nitipong Permpalung MD
    Doug Powell MD
    Harold S. Rabinovitz MD
    Christopher J. Rapuano MD
    Sireesha Reddy MD
    Angela Restrepo MD, PhD
    Bertrand Richert MD, PhD
    J. Martin Rodriguez, MD, FACP
    Theodore Rosen MD
    Misha Rosenbach MD
    Scott Schiffman MD
    Robert H. Schosser MD
    Glynis A. Scott MD
    Carlos Seas MD, MSc
    Deniz Seçkin MD
    Daniel Sexton MD
    Paul K. Shitabata MD
    Tor Shwayder MD, FAAP, FAAD
    Elaine Siegfried MD
    Gene Sienkiewicz MD
    Christye Sisson
    Mary J. Spencer MD, FAAP
    Sarah Stein MD
    William Van Stoecker MD
    Frances J. Storrs MD
    Erik J. Stratman MD
    Lindsay C. Strowd MD
    Erika Summers MD
    Belinda Tan MD, PhD
    Robert Tomsick MD
    Jenny Valverde MD
    Vishalakshi Viswanath MD
    Susan Voci MD
    Lisa Wallin ANP, FCCWS
    Douglas Walsh MD
    Ryan R. Walsh MD
    George Watt MD
    Clayton E. Wheeler MD
    Sally-Ann Whelan MS, NP, CWOCN
    Jan Willems MD, PhD
    James Henry Willig MD, MPH
    Karen Wiss MD
    Vivian Wong MD, PhD
    Sook-Bin Woo MS, DMD, MMSc
    Jamie Woodcock MD
    Stephen J. Xenias MD
    Lisa Zaba MD
    Vijay Zawar MD
    Bonnnie Zhang MD
    Carolyn Ziemer MD


  • Am. Journal of Trop. Med & Hygiene
  • Armed Forces Pest Management Board
  • Blackwell Publishing
  • Bugwood Network
  • Centers For Disease Control and Prevention
  • Centro Internacional de Entrenamiento e Investigaciones Mèdicas (CIDEIM)
  • Dermatology Online Journal
  • East Carolina University (ECU), Division of Dermatology
  • International Atomic Energy Agency
  • Massachusetts Medical Society
  • Oxford University Press
  • Radiological Society of North America
  • Washington Hospital Center
  • Wikipedia
  • World Health Organization
ContentsSynopsisCodesLook ForDiagnostic PearlsDifferential Diagnosis & PitfallsBest TestsManagement PearlsTherapyAssociated MedicationsReferencesView all Images (4)
Drug-induced lupus erythematosus - Drug Reactions
Other Resources UpToDate PubMed

Drug-induced lupus erythematosus - Drug Reactions

Print Images (4)
Contributors: Art Papier MD, Jeffrey D. Bernhard MD, Belinda Tan MD, PhD, Michael D. Tharp MD, Neil Shear MD
Other Resources UpToDate PubMed


The term "drug-induced lupus erythematosus" refers to several distinct entities including drug-induced systemic lupus erythematosus, drug-induced subacute cutaneous lupus erythematosus, and drug-induced chronic cutaneous lupus erythematosus. In this article we discuss drug-induced systemic lupus erythematous.

Drug-induced systemic lupus erythematosus (SLE) is an autoimmune disease in which hypersensitivity reactions to a medication lead to formation of autoantibodies. Clinical manifestations may be similar to those seen in idiopathic lupus, but the difference is that they are related to continuous drug exposure (more than 1 month); cessation of symptoms occurs upon discontinuation of the drug.

Drug-induced SLE also varies in its serology, with anti-nuclear and anti-histone antibodies being the predominant type in drug-induced lupus and anti-nuclear and anti-double-stranded DNA being the major autoantibodies in idiopathic SLE.

Drugs can act in more than one way on SLE: they can trigger a flare or exacerbate pre-existing SLE, they can trigger the first onset of SLE in pre-disposed patients, and they may engender drug-induced lupus in patients who have no previous history of SLE and whose illness remits when the offending drug is discontinued.

In most types of drug-induced lupus, the general prodromal complaints in more than 80% of cases are arthralgias and arthritis. These are followed by constitutional symptoms of fever, fatigue, anorexia and weight loss, which gradually worsens over time. Additional symptoms include dry cough, shortness of breath, and occasionally effusion into serous spaces leading to pleuritis and pericardial effusion.

Drug-induced SLE can be further subdivided into the classic form, which is the type seen with the majority of drugs, and the form due to anti-tumor necrosis factor (TNF)-alpha drugs.

Classic drug-induced SLE (due to drugs such as procainamide and hydralazine):
  • This type of lupus occurs in an older age group, with equal incidence among males and females.
  • Skin findings are less common in drug-induced SLE than in idiopathic SLE. If there is cutaneous involvement, photosensitivity, purpura, and erythema nodosum predominate as opposed to the typical skin findings of idiopathic SLE such as malar rash, oral ulcers, alopecia, and discoid lesions.
  • When cutaneous manifestations predominate, renal involvement and neurologic symptoms are less frequent.
Many drugs show individual variation:
  • Procainamide (20% incidence) is associated with pulmonary involvement. It causes serositis and both pleural and pericardial effusions. Myalgias are also more common.
  • Hydralazine (5% to 8 % incidence) is associated with arthritis and with a higher frequency of cutaneous involvement (but not the typical butterfly rash seen in SLE).
  • Quinidine-induced lupus is also associated with a higher incidence of rash.
  • Minocycline used for acne in young females has sometimes led to the onset of arthralgias, polyarthritis, fever and rash, early morning stiffness, and myalgias. Minocycline can also lead to hepatic involvement with raised liver enzymes and autoimmune hepatitis.
  • D-penicillamine may lead to nephrotoxicity, which is not in line with the usual pattern of drug-induced lupus manifestations.
Drug-induced SLE due to anti-TNF-alpha:
  • As with the classic form of drug-induced SLE, symptoms are usually less severe than those seen in idiopathic SLE. However, there is a greater degree of cutaneous, renal, and CNS involvement compared with the classic form of drug-induced lupus. Antibody type also varies, with double-stranded DNA being more common in drug-induced lupus related to anti-TNF-alpha. Culprit drugs include infliximab, adalimumab, and etanercept.
  • Other symptoms include hematological abnormalities, photosensitivity, oral ulcers, and arthritis.
  • With these drugs (eg, infliximab), cutaneous manifestations are a predominant feature. Infliximab induces discoid plaques similar to those seen in idiopathic SLE. Etanercept has also been reported to produce discoid-like lesions or a nonspecific dermatitis.
  • These drugs also induce lupus-like complications that include pericarditis, pleural or pericardial effusions, and polyarthritis. Visceral involvement of the kidneys and liver, which is rare in the classic form, has been reported. Dasatinib, for example, has been cited as causing hepatosplenomegaly, pleural effusion, and pericardial effusion. Anti-double-stranded DNA antibodies and anti-nuclear antibodies are formed.
In both groups of drug-induced lupus, onset of symptoms may appear anywhere from within a couple of weeks to 4 years after the start of therapy. Symptoms are usually mild to moderate and usually resolve within days to months after discontinuation of the drug. Resolution of symptoms acts as a good differentiating point between drug-induced and idiopathic SLE.

The incidence of drug-induced lupus is estimated to be at around 10% of all cases of idiopathic SLE, with 15,000 to 20,000 newly diagnosed cases every year.

Certain genetic factors predispose to the development of drug-induced lupus. Slow acetylators may develop symptoms when on medications such as procainamide and hydralazine. Other predisposing factors are the dose and duration of a given drug; usually months to years of drug exposure has occurred before the onset of symptoms. In this respect, drug-induced SLE differs markedly from other varieties of drug hypersensitivity reactions.

Elderly patients are most often affected (with both sexes equally affected), as they are exposed to a large number of medications.

Most common drugs causing lupus:
  • Procainamide
  • Hydralazine
  • Isoniazid
  • Chlorpromazine
  • Quinidine
  • D-Penicillamine
  • Minocycline
Anti-TNF-alpha drugs causing lupus:
  • Etanercept
  • Infliximab
  • Dasatinib
  • Adalimumab


M32.0 – Drug-induced systemic lupus erythematosus

80258006 – Drug-induced lupus erythematosus

Look For

Subscription Required

Diagnostic Pearls

Subscription Required

Differential Diagnosis & Pitfalls

Best Tests

Subscription Required

Management Pearls

Subscription Required


Subscription Required

Associated Medications

Subscription Required


Subscription Required

Last Updated: 10/26/2017
Copyright © 2018 VisualDx®. All rights reserved.
Drug-induced lupus erythematosus - Drug Reactions
Print 4 Images
View all Images (4)
(with subscription)
Drug-induced lupus erythematosus (Classic Presentation) : Fatigue, Fever, ANA positive, Anti-histone antibodies, Reaction 1 month to 1 year after drug, Weight loss, Arthralgia, Dyspnea
Clinical image of Drug-induced lupus erythematosus
Copyright © 2018 VisualDx®. All rights reserved.